Multimedia
Video

Quarterly intravenous eptinezumab prevents migraine
PHILADELPHIA – Results from a pair of dose-ranging, randomized studies showed one IV eptinezumab dose cut migraine recurrences for 3 months.
Conference Coverage

Nearly 20% of migraineurs use opioids for migraine
PHILADELPHIA – People with 4 or more migraine headache days per month are more likely to use opioids, compared with people with fewer migraine...
Conference Coverage

White light exposure is associated with acute risk of headache in migraine
PHILADELPHIA – Whether reducing light exposure could decrease headache frequency is unclear, said the investigators...
Conference Coverage

Which migraineurs seek care from a neurologist?
PHILADELPHIA – A large number of patients with migraine who first seek care for migraine in a primary care setting receive an initial migraine...
Conference Coverage

Can mindfulness-based cognitive therapy treat migraine?
PHILADELPHIA – Mindfulness-based cognitive therapy for migraine may reduce migraine-related disability, even as the number of headache days and...
Conference Coverage

Telemedicine migraine consults are as effective as in-office visits
PHILADELPHIA - Follow-up telemedicine consultations with migraine patients produced outcomes similar to patients managed in office in a randomized...
Conference Coverage

How does gender bias affect the headache field?
PHILADELPHIA – Many female headache specialists report having experienced sexual harassment in the workplace, and...
Video

Patient registry sheds light on the economic impact of MS
SEATTLE – Dr. Kottil Rammohan discusses the extent to which multiple sclerosis limits patients’ potential at work and at home.
Video

Steady advances made since recognition of neuromyelitis optica 20 years ago
SEATTLE – Dr. Brian Weinshenker discusses the progress made in understanding and managing neuromyelitis optica.
Video

Developing new measurements for better MS outcomes
SEATTLE – Researchers are working on developing more sensitive ways of measuring MS disease status.